BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

798 related articles for article (PubMed ID: 17536186)

  • 1. Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels.
    Rakover I; Arbel M; Solomon B
    Neurodegener Dis; 2007; 4(5):392-402. PubMed ID: 17536186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
    Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
    J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets.
    Evin G; Zhu A; Holsinger RM; Masters CL; Li QX
    J Neurosci Res; 2003 Nov; 74(3):386-92. PubMed ID: 14598315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1.
    Sankaranarayanan S; Price EA; Wu G; Crouthamel MC; Shi XP; Tugusheva K; Tyler KX; Kahana J; Ellis J; Jin L; Steele T; Stachel S; Coburn C; Simon AJ
    J Pharmacol Exp Ther; 2008 Mar; 324(3):957-69. PubMed ID: 18156464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production.
    Arendash GW; Schleif W; Rezai-Zadeh K; Jackson EK; Zacharia LC; Cracchiolo JR; Shippy D; Tan J
    Neuroscience; 2006 Nov; 142(4):941-52. PubMed ID: 16938404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel approaches for immunotherapeutic intervention in Alzheimer's disease.
    Vasilevko V; Cribbs DH
    Neurochem Int; 2006 Jul; 49(2):113-26. PubMed ID: 16765487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.
    Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS
    J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibiting β-secretase activity in Alzheimer's disease cell models with single-chain antibodies specifically targeting APP.
    Boddapati S; Levites Y; Sierks MR
    J Mol Biol; 2011 Jan; 405(2):436-47. PubMed ID: 21073877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice.
    Asai M; Hattori C; Iwata N; Saido TC; Sasagawa N; Szabó B; Hashimoto Y; Maruyama K; Tanuma S; Kiso Y; Ishiura S
    J Neurochem; 2006 Jan; 96(2):533-40. PubMed ID: 16336629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity.
    Imbimbo BP; Del Giudice E; Colavito D; D'Arrigo A; Dalle Carbonare M; Villetti G; Facchinetti F; Volta R; Pietrini V; Baroc MF; Serneels L; De Strooper B; Leon A
    J Pharmacol Exp Ther; 2007 Dec; 323(3):822-30. PubMed ID: 17895400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-dependent differential expression of BACE splice variants in brain regions of tg2576 mice.
    Zohar O; Pick CG; Cavallaro S; Chapman J; Katzav A; Milman A; Alkon DL
    Neurobiol Aging; 2005; 26(8):1167-75. PubMed ID: 15917100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of amyloid beta-peptide production by blockage of beta-secretase cleavage site of amyloid precursor protein.
    Na CH; Jeon SH; Zhang G; Olson GL; Chae CB
    J Neurochem; 2007 Jun; 101(6):1583-95. PubMed ID: 17542811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1.
    Ohno M; Chang L; Tseng W; Oakley H; Citron M; Klein WL; Vassar R; Disterhoft JF
    Eur J Neurosci; 2006 Jan; 23(1):251-60. PubMed ID: 16420434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Excess of nicastrin in brain results in heterozygosity having no effect on endogenous APP processing and amyloid peptide levels in vivo.
    Brijbassi S; Amtul Z; Newbigging S; Westaway D; St George-Hyslop P; Rozmahel RF
    Neurobiol Dis; 2007 Feb; 25(2):291-6. PubMed ID: 17071095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice.
    Nishitomi K; Sakaguchi G; Horikoshi Y; Gray AJ; Maeda M; Hirata-Fukae C; Becker AG; Hosono M; Sakaguchi I; Minami SS; Nakajima Y; Li HF; Takeyama C; Kihara T; Ota A; Wong PC; Aisen PS; Kato A; Kinoshita N; Matsuoka Y
    J Neurochem; 2006 Dec; 99(6):1555-63. PubMed ID: 17083447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor.
    Barten DM; Guss VL; Corsa JA; Loo A; Hansel SB; Zheng M; Munoz B; Srinivasan K; Wang B; Robertson BJ; Polson CT; Wang J; Roberts SB; Hendrick JP; Anderson JJ; Loy JK; Denton R; Verdoorn TA; Smith DW; Felsenstein KM
    J Pharmacol Exp Ther; 2005 Feb; 312(2):635-43. PubMed ID: 15452193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beneficial effects of quetiapine in a transgenic mouse model of Alzheimer's disease.
    He J; Luo H; Yan B; Yu Y; Wang H; Wei Z; Zhang Y; Xu H; Tempier A; Li X; Li XM
    Neurobiol Aging; 2009 Aug; 30(8):1205-16. PubMed ID: 18079026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing.
    Marcade M; Bourdin J; Loiseau N; Peillon H; Rayer A; Drouin D; Schweighoffer F; Désiré L
    J Neurochem; 2008 Jul; 106(1):392-404. PubMed ID: 18397369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imipramine, in part through tumor necrosis factor alpha inhibition, prevents cognitive decline and beta-amyloid accumulation in a mouse model of Alzheimer's disease.
    Chavant F; Deguil J; Pain S; Ingrand I; Milin S; Fauconneau B; Pérault-Pochat MC; Lafay-Chebassier C
    J Pharmacol Exp Ther; 2010 Feb; 332(2):505-14. PubMed ID: 19889791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promising multifunctional anti-Alzheimer's dimer bis(7)-Cognitin acting as an activator of protein kinase C regulates activities of alpha-secretase and BACE-1 concurrently.
    Fu H; Dou J; Li W; Cui W; Mak S; Hu Q; Luo J; Lam CS; Pang Y; Youdim MB; Han Y
    Eur J Pharmacol; 2009 Nov; 623(1-3):14-21. PubMed ID: 19765582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.